![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AbbVie Subsidiary Moves to Acquire Soliton, RAP Device for $550 Million
AbbVie Subsidiary Moves to Acquire Soliton, RAP Device for $550 Million
![Acquires -Acquired](https://www.fdanews.com/ext/resources/test/Device_Images6/Acquired-Acquires.gif?t=1604445798&width=430)
AbbVie’s Allergan Aesthetics will purchase rapid acoustic pulse devicemaker Soliton for $550 million in a move to expand its body contouring treatment product range.
Through the agreement, Allergan Aesthetics will acquire Soliton’s Resonic device, a non-invasive rapid acoustic pulse system cleared by the FDA for the short-term improvement of cellulite appearance and for tattoo removal when used with a laser.
The device uses rapid, high-frequency sound waves to disrupt cellular structures and connective tissue and reduce the dimpled appearance of cellulite.
Upcoming Events
-
21Oct